Real-World Foslevodopa/Foscarbidopa: OFF Time Falls 2.8 Hours, With 27.6% Early Discontinuation
This first multicountry real-world interim dataset shows whether the pivotal-trial OFF time benefit of 24-hour subcutaneous levodopa prodrug infusion holds in routine practice, and where tolerability and attrition remain concerns.
📅 Journal publication: Aug 2026(online May 7, 2026)·Last updated: Nov 20, 2026
Six-month interim data shows promise for 24-hour Parkinson's infusion.
Continuous subcutaneous infusion could offer improved management of motor fluctuations in advanced Parkinson's disease. A significant reduction in OFF time by 2.8 hours and improvements in quality of life metrics over six months. While promising, the study is an interim analysis with a limited patient cohort and requires further results for comprehensive conclusions. Foslevodopa/foscarbidopa reduces OFF time and enhances quality of life in advanced Parkinson's patients.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Jost WH, Bergquist F, Evans A, Hassin-Baer S, Hauser RA, Henriksen T, Malaty IA, Mestre TA, Mir P, Rodriguez R, Schwingenschuh P, Simu M, Bergmann L, Zhou TT, Caughlin S, Gopalkrishnan M, Kukreja P, O'Meara M, Parra JC, Shah MB, Aldred J
Citation:Jost WH, Bergquist F, Evans A, et al. Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results. Neurology and therapy. 2026;15(4):1743-1762. doi:10.1007/s40120-026-00948-6